Related Experiment Videos
Thromboembolic complications in atrial fibrillation
1Department of Neurology, University Hospital, Rigshospitalet, Copenhagen, Denmark.
Stroke
|January 1, 1990
Summary
Patients with atrial fibrillation face a significantly higher risk of thromboembolic complications. Anticoagulation with warfarin effectively reduces these risks in chronic atrial fibrillation patients.
Area of Science:
- Cardiology
- Neurology
- Thrombosis Research
Background:
- Nonrheumatic atrial fibrillation (AF) increases thromboembolic complication risk 5-7 fold compared to sinus rhythm.
- Chronic AF poses a higher risk than paroxysmal AF, with stroke incidence varying.
- Clinical risk factors like heart failure and hypertension are implicated, but specific high-risk subgroups remain unclear.
Purpose of the Study:
- To review current understanding of thromboembolic complications in nonrheumatic atrial fibrillation.
- To discuss prevention strategies, focusing on anticoagulation.
- To evaluate risk factors and outcomes associated with atrial fibrillation.
Main Methods:
- Literature review of studies on atrial fibrillation, thromboembolism, and stroke prevention.
- Analysis of risk factors including heart failure, hypertension, and atrial size.
- Examination of cerebral blood flow changes and silent cerebral infarction prevalence.
Main Results:
- Chronic AF carries a 3-6% annual thromboembolic risk; paroxysmal AF has a lower risk.
- Warfarin anticoagulation significantly reduced thromboembolic complications in a prospective study.
- Silent cerebral infarction is prevalent in chronic AF but rare in paroxysmal AF.
Conclusions:
- Anticoagulation is a proven strategy for stroke prevention in nonrheumatic chronic atrial fibrillation.
- Further research is needed to identify specific high-risk subgroups.
- Understanding AF's impact on cerebral blood flow and infarction is crucial.